-83%

est. 2Y upside i

HealthcareSeed

Pioneering Breast Cancer Diagnostics for a Healthier Tomorrow

Rank

#150

Sector

Medical Devices

Est. Liquidity

~5Y

Data Quality

Data: Medium

This opportunity presents a high-risk, moderate-upside proposition driven by Digistain's innovative and accessible breast cancer diagnostic technology, which has the potential to disrupt a market dominated by slower, more expensive solutions, but requires a long-term view given the early stage and significant hurdles ahead.

Last updated: February 16, 2026

Bull (35%)+400%

Digistain achieves significant market penetration globally, secures FDA approval, and is acquired by a large medical device or diagnostics company at a premium valuation.

Base (35%)+100%

Digistain continues steady growth and regional expansion, establishing itself as a strong niche player, leading to a modest acquisition or further funding rounds at a reasonable valuation.

Bear (30%)-90%

Digistain faces significant challenges in regulatory approval or market adoption, struggles against incumbent competition, or runs out of capital before achieving critical mass.

Est. time to liquidity~5.0 years
View all 14 open roles at Digistain →

Last updated: March 10, 2026

Community

Valuation Sentiment

Our model estimates -83% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.